PCSA
Processa Pharmaceuticals, Inc.
Biotechnology
Market Cap$7M
5Y Perf.-98.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PCSA vs CRVS
Revenue, margins, valuation, and 5-year total return — side by side.
CRVS
Corvus Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.23B
5Y Perf.+350.7%
PCSA vs CRVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PCSA | CRVS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $7M | $1.23B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-14M | $-44M |
| Total Debt | $0.00 | $937K |
| Cash & Equiv. | $6M | $5M |
PCSA vs CRVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PCSA
CRVS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Processa Pharmaceut… (PCSA) | 100 | 1.7 | -98.3% |
| Corvus Pharmaceutic… (CRVS) | 100 | 450.7 | +350.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PCSA vs CRVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CRVS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Processa Pharmaceuticals, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PCSA
Processa Pharmaceuticals, Inc.
The Growth Play
PCSA is the clearest fit if your priority is growth exposure.
- EPS growth 89.3%
- +10.1% vs CRVS's +355.9%
Best for: growth exposure
CRVS
Corvus Pharmaceuticals, Inc.
The Income Pick
CRVS carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.63
- 17.1% 10Y total return vs PCSA's -93.8%
- Lower volatility, beta 1.63, Low D/E 1.5%, current ratio 6.21x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CRVS | -6.6% revenue growth vs PCSA's -14.5% |
| Quality / Margins | CRVS | 3.5% margin vs PCSA's 1.4% |
| Stability / Safety | CRVS | Beta 1.63 vs PCSA's 1.72 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | PCSA | +10.1% vs CRVS's +355.9% |
| Efficiency (ROA) | CRVS | -35.7% ROA vs PCSA's -191.1%, ROIC -78.1% vs -33.9% |
PCSA vs CRVS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCRVSLAGGINGPCSA
PCSAProcessa Pharmaceutic…
1leads
CRVSCorvus Pharmaceutical…
3leads
6 Total Categories
CATEGORYLEADERvs PCSAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PCSA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CRVS4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
CRVS5/6
Risk & VolatilityBeta, volatility, and downside exposure
CRVS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PCSA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
PCSA and CRVS operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | PCSAProcessa Pharmace… | CRVSCorvus Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$14M | -$48M |
| Net IncomeAfter-tax profit | -$14M | -$44M |
| Free Cash FlowCash after capex | -$14M | -$35M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +93.3% | -15.4% |
PCSA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — PCSA and CRVS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | PCSAProcessa Pharmace… | CRVSCorvus Pharmaceut… |
|---|---|---|
| Market CapShares × price | $7M | $1.2B |
| Enterprise ValueMkt cap + debt − cash | $2M | $1.2B |
| Trailing P/EPrice ÷ TTM EPS | -0.28x | -27.53x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.67x | 19.01x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — PCSA and CRVS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CRVS leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
CRVS delivers a -38.9% return on equity — every $100 of shareholder capital generates $-39 in annual profit, vs $-3 for PCSA.
| Metric | PCSAProcessa Pharmace… | CRVSCorvus Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -2.6% | -38.9% |
| ROA (TTM)Return on assets | -191.1% | -35.7% |
| ROICReturn on invested capital | -33.9% | -78.1% |
| ROCEReturn on capital employed | -3.8% | -90.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | -$6M | -$4M |
| Cash & Equiv.Liquid assets | $6M | $5M |
| Total DebtShort + long-term debt | $0 | $937,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -18.29x |
CRVS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
CRVS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CRVS five years ago would be worth $50,137 today (with dividends reinvested), compared to $208 for PCSA. Over the past 12 months, PCSA leads with a +1014.1% total return vs CRVS's +355.9%. The 3-year compound annual growth rate (CAGR) favors CRVS at 123.9% vs PCSA's -41.0% — a key indicator of consistent wealth creation.
| Metric | PCSAProcessa Pharmace… | CRVSCorvus Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -2.0% | +99.3% |
| 1-Year ReturnPast 12 months | +1014.1% | +355.9% |
| 3-Year ReturnCumulative with dividends | -79.5% | +1022.3% |
| 5-Year ReturnCumulative with dividends | -97.9% | +401.4% |
| 10-Year ReturnCumulative with dividends | -93.8% | +17.1% |
| CAGR (3Y)Annualised 3-year return | -41.0% | +123.9% |
CRVS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
CRVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CRVS is the less volatile stock with a 1.63 beta — it tends to amplify market swings less than PCSA's 1.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRVS currently trades 54.1% from its 52-week high vs PCSA's 32.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PCSAProcessa Pharmace… | CRVSCorvus Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.81x | 1.57x |
| 52-Week HighHighest price in past year | $8.88 | $26.95 |
| 52-Week LowLowest price in past year | $0.11 | $3.17 |
| % of 52W HighCurrent price vs 52-week peak | +32.3% | +54.1% |
| RSI (14)Momentum oscillator 0–100 | 49.1 | 49.2 |
| Avg Volume (50D)Average daily shares traded | 53K | 1.2M |
CRVS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PCSA as "Buy" and CRVS as "Buy". Consensus price targets imply 213.6% upside for PCSA (target: $9) vs 127.3% for CRVS (target: $33).
| Metric | PCSAProcessa Pharmace… | CRVSCorvus Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $33.17 |
| # AnalystsCovering analysts | 5 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CRVS leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). PCSA leads in 1 (Income & Cash Flow). 1 tied.
Best OverallCorvus Pharmaceuticals, Inc. (CRVS)Leads 3 of 6 categories
Loading custom metrics...
PCSA vs CRVS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PCSA or CRVS a better buy right now?
Analysts rate Processa Pharmaceuticals, Inc.
(PCSA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PCSA or CRVS?
Over the past 5 years, Corvus Pharmaceuticals, Inc.
(CRVS) delivered a total return of +401. 4%, compared to -97. 9% for Processa Pharmaceuticals, Inc. (PCSA). Over 10 years, the gap is even starker: CRVS returned +24. 8% versus PCSA's -94. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PCSA or CRVS?
By beta (market sensitivity over 5 years), Corvus Pharmaceuticals, Inc.
(CRVS) is the lower-risk stock at 1. 57β versus Processa Pharmaceuticals, Inc. 's 1. 81β — meaning PCSA is approximately 15% more volatile than CRVS relative to the S&P 500.
04Which is growing faster — PCSA or CRVS?
On earnings-per-share growth, the picture is similar: Processa Pharmaceuticals, Inc.
grew EPS 89. 3% year-over-year, compared to 48. 0% for Corvus Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PCSA or CRVS?
Processa Pharmaceuticals, Inc.
(PCSA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Corvus Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PCSA leads at 0. 0% versus 0. 0% for CRVS. At the gross margin level — before operating expenses — PCSA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PCSA or CRVS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PCSA or CRVS better for a retirement portfolio?
For long-horizon retirement investors, Corvus Pharmaceuticals, Inc.
(CRVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Processa Pharmaceuticals, Inc. (PCSA) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRVS: +24. 8%, PCSA: -94. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PCSA and CRVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.